Share

Recursion Pharmaceuticals Inc (RXRX.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 18 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Price-adjusted rating

Partial Sell

5-Year Return Est.

-10.2%

RXRX.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

The central tension is that Recursion is doing the right things too slowly for its own balance sheet. Cost discipline has genuinely extended survival, partner validation continues, and REC-4881 produced the most convincing clinical signal in the company's history. Yet $556.8 million of cash meets roughly $375 million of annual cash opex, and a $300 million ATM sits ready [1][2][5]. The base case is therefore neither collapse nor re-rating: clinical progress accrues, a financing takes a bite out of per-share value during 2027-2028, and the share price ends the horizon near where it started, having travelled violently in between.

Cash opex of $375 million against $54.9 million TTM revenue implies roughly $1.3 billion of external funding needed by 2031.
At a $2.04 billion market cap, that funding equals 40-60% unless a catalyst lifts the issuance price first.
Enterprise value near $1.5 billion net of cash values seven early assets at roughly $210 million each.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-15	23.9
Observed price	2021-09-19	26.3
Observed price	2021-10-05	21.3
Observed price	2021-10-13	19.74
Observed price	2021-10-25	18.26
Observed price	2021-11-02	20.7
Observed price	2021-11-10	16.14
Observed price	2021-12-08	19.81
Observed price	2021-12-16	17.70
Observed price	2021-12-20	19.29
Observed price	2022-01-09	15.56
Observed price	2022-01-13	13.90
Observed price	2022-01-29	11.10
Observed price	2022-02-10	11.79
Observed price	2022-02-22	10.16
Observed price	2022-03-02	10.74
Observed price	2022-03-14	6.16
Observed price	2022-04-03	7.76
Observed price	2022-04-07	6.69
Observed price	2022-04-19	6.48
Observed price	2022-05-09	5.56
Observed price	2022-05-25	5.49
Observed price	2022-06-02	6.49
Observed price	2022-06-14	6.20
Observed price	2022-06-22	8.56
Observed price	2022-07-12	8.00
Observed price	2022-07-20	8.99
Observed price	2022-07-24	7.84
Observed price	2022-08-13	12.35
Observed price	2022-08-17	11.52
Observed price	2022-08-21	9.70
Observed price	2022-09-14	13.47
Observed price	2022-09-26	9.97
Observed price	2022-10-04	11.84
Observed price	2022-10-20	10.33
Observed price	2022-11-05	9.56
Observed price	2022-11-13	12.63
Observed price	2022-12-07	9.33
Observed price	2022-12-11	8.79
Observed price	2022-12-15	8.47
Observed price	2022-12-27	7.16
Observed price	2023-01-08	7.49
Observed price	2023-01-16	9.06
Observed price	2023-02-05	9.28
Observed price	2023-02-21	7.71
Observed price	2023-03-05	8.30
Observed price	2023-03-17	7.41
Observed price	2023-03-21	7.43
Observed price	2023-04-10	6.52
Observed price	2023-04-18	5.94
Observed price	2023-04-30	4.78
Observed price	2023-05-16	5.13
Observed price	2023-05-24	8.96
Observed price	2023-06-05	8.43
Observed price	2023-06-13	9.94
Observed price	2023-07-11	6.78
Observed price	2023-07-15	12.40
Observed price	2023-07-19	15.86
Observed price	2023-08-08	11.55
Observed price	2023-08-12	9.49
Observed price	2023-08-24	8.57
Observed price	2023-09-05	8.70
Observed price	2023-09-25	7.69
Observed price	2023-09-29	7.65
Observed price	2023-10-19	6.05
Observed price	2023-10-31	5.28
Observed price	2023-11-04	5.78
Observed price	2023-11-16	6.67
Observed price	2023-12-06	7.42
Observed price	2023-12-10	7.57
Observed price	2023-12-26	10.79
Observed price	2024-01-07	12.38
Observed price	2024-01-19	9.63
Observed price	2024-02-04	9.18
Observed price	2024-02-16	13.15
Observed price	2024-02-24	13.83
Observed price	2024-03-11	10.37
Observed price	2024-03-15	11.22
Observed price	2024-04-04	8.73
Observed price	2024-04-08	9.00
Observed price	2024-04-20	7.43
Observed price	2024-05-10	8.60
Observed price	2024-05-14	10.05
Observed price	2024-06-07	8.51
Observed price	2024-06-15	9.30
Observed price	2024-06-19	9.43
Observed price	2024-07-05	7.32
Observed price	2024-07-17	8.35
Observed price	2024-08-02	7.02
Observed price	2024-08-10	6.20
Observed price	2024-08-26	7.89
Observed price	2024-08-30	7.28
Observed price	2024-09-07	5.99
Observed price	2024-09-27	6.98
Observed price	2024-10-05	6.13
Observed price	2024-11-02	6.48
Observed price	2024-11-06	6.97
Observed price	2024-11-10	7.59
Observed price	2024-11-22	5.70
Observed price	2024-12-08	8.18
Observed price	2024-12-20	6.03
Observed price	2025-01-05	7.90
Observed price	2025-01-17	6.53
Observed price	2025-01-21	6.88
Observed price	2025-02-10	7.65
Observed price	2025-02-18	10.64
Observed price	2025-03-06	6.24
Observed price	2025-03-22	6.72
Observed price	2025-03-30	5.46
Observed price	2025-04-07	4.20
Observed price	2025-04-11	5.76
Observed price	2025-04-27	5.80
Observed price	2025-05-09	4.33
Observed price	2025-05-21	4.09
Observed price	2025-06-06	5.49
Observed price	2025-06-22	4.90
Observed price	2025-06-26	5.40
Observed price	2025-07-12	5.28
Observed price	2025-07-28	6.31
Observed price	2025-08-13	5.70
Observed price	2025-08-21	4.78
Observed price	2025-08-25	4.83
Observed price	2025-09-10	4.54
Observed price	2025-09-26	4.72
Observed price	2025-10-08	6.09
Observed price	2025-10-12	5.46
Observed price	2025-10-20	6.68
Observed price	2025-11-05	4.96
Observed price	2025-11-17	4.12
Observed price	2025-12-07	4.78
Observed price	2025-12-15	4.20
Observed price	2025-12-31	4.09
Observed price	2026-01-12	4.81
Observed price	2026-01-24	4.68
Observed price	2026-02-05	3.56
Observed price	2026-02-09	3.98
Observed price	2026-02-21	3.42
Observed price	2026-03-05	3.54
Observed price	2026-03-25	3.17
Observed price	2026-03-29	2.87
Observed price	2026-04-18	3.75
Observed price	2026-04-22	3.73
Observed price	2026-05-12	3.15
Observed price	2026-05-16	2.92
Observed price	2026-06-01	3.79
Observed price	2026-06-17	3.11
Observed price	2026-06-29	3.69
Observed price	2026-07-07	3.84
Observed price	2026-07-19	2.91
Observed price	2026-07-31	3.00
Observed price	2026-08-04	3.31
Observed price	2026-09-05	3.58
Observed price	2026-09-09	3.21
Observed price	2026-09-13	3.34
Observed price	2026-09-22	4.05
Observed price	2026-09-25	3.74
Published advisor forecast	2026-09-18	3.83
Published advisor forecast	2026-12-18	4.06
Published advisor forecast	2027-03-18	3.74
Published advisor forecast	2027-06-18	3.55
Published advisor forecast	2027-09-18	3.69
Published advisor forecast	2027-12-18	3.17
Published advisor forecast	2028-03-18	3.33
Published advisor forecast	2028-06-18	3.43
Published advisor forecast	2028-09-18	3.23
Published advisor forecast	2028-12-18	3.36
Published advisor forecast	2029-03-18	3.25
Published advisor forecast	2029-06-18	3.42
Published advisor forecast	2029-09-18	3.21
Published advisor forecast	2029-12-18	3.31
Published advisor forecast	2030-03-18	3.24
Published advisor forecast	2030-06-18	3.44
Published advisor forecast	2030-09-18	3.27
Published advisor forecast	2030-12-18	3.36
Published advisor forecast	2031-03-18	3.30
Published advisor forecast	2031-06-18	3.43
Published advisor forecast	2031-09-18	3.36

2. Scenarios & Signals

Bull case

The bull case activates if the FDA endorses polyp burden as a registrational endpoint before the cash runway forces a raise. That single sequencing change flips the reflexive loop: a defined NDA timeline lifts the share price, which turns the ATM from a dilution threat into cheap, opportunistic capital, which funds REC-617 and REC-3565 readouts in 1H27 from strength rather than desperation. Partner interest then intensifies, and the platform is repriced as scarce infrastructure rather than a cost centre.

Bear case

The bear case activates when a disappointing regulatory response meets a depleted treasury in the same quarter. Loss of the lead asset's credibility forces financing into weakness, and each discounted tranche lowers the price at which the next tranche must clear. Management then cuts opex again, slowing the very programs that justify the remaining valuation, while a 2.77 beta amplifies every macro downdraft. The result is a self-reinforcing descent toward cash value with the platform assigned little worth.

Current crowd narrative

The tape and the sell side are telling opposite stories. Seven analysts carry a Buy consensus with a $7.22 average target, roughly double the $3.83 close, while the stock sits 84.5% below its five-year peak [19][22]. Consensus treats the Roche relationship and AI-discovery narrative as settled validation and anchors on headline partnership value, quietly assuming the next financing is painless.

Alpha-gap assessment

The crowd modestly overestimates these shares, but the error is not about the science. Sell-side targets near $7 discount a successful FAP filing while ignoring the arithmetic: $556.8 million cash against roughly $375 million annual cash opex implies exhaustion near end-2027, and a $300 million ATM sits pre-loaded [1][2][5]. Management extended runway guidance by cutting costs, not raising capital, which is disciplined and also an admission. Per-share option value is therefore taxed before any clinical outcome resolves.

Convergence catalyst

The FDA registrational-path update for REC-4881, expected around late 2026 into 2027, is the trigger [11][23]. It converts an open-ended option into a datable timeline or a broken one. The first observable sign of repricing will be ATM utilisation disclosed in the following 10-Q.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.3
Expected volatility regime: high_erratic
Convergence-cycle position: stabilization

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Fap: AN Empty Regulatory Field	REC-4881 at 4 mg QD reduced total polyp burden in 75% of evaluable patients, median 43% at twelve weeks, with durability off therapy and no Grade 4-plus treatment-related events [10]. Familial adenomatous polyposis has no approved pharmacotherapy, so an orphan-scale approval would give this loss-making company its first product revenue line. The absence of precedent is precisely what creates the option value investors are paying for.	Not available	+28.0%
BURN Discipline BUYS Eighteen Months	Management cut 2026 cash operating expense guidance to $375 million, and Q2 total operating costs fell to $142.6 million from $195.5 million a year earlier [2][4]. Lower Tempus data purchases and post-Exscientia headcount reductions convert narrative restraint into real cash preservation, extending stated runway into early 2028 [1][2]. This is the single most credible value-protecting action available to a platform company with $54.9 million TTM revenue.	Not available	+16.0%
Pharma Partners FUND THE Laboratory	Cumulative partnership inflows exceed $500 million, including $216 million from Roche/Genentech, with Sanofi, Bayer and Merck KGaA agreements carrying non-risk-adjusted headline value [12][13]. Genentech advancing the collaboration's first neuroscience target into joint early discovery in August 2026 is fresh third-party validation of the maps-and-models platform [14]. Each milestone is small against a $375 million burn, but the channel is non-dilutive and recurring, directly reducing required equity issuance.	Not available	+13.0%
Founder Exits Operator Arrives	Najat Khan replaced co-founder Chris Gibson as CEO on January 1, 2026, and Gibson declined board re-election after June 2026 [13][16]. A clean founder exit within seven months removes the sunk-cost defender of a sprawling pipeline and has already coincided with pruning and two successive opex guidance cuts [2][3]. Capital allocation shifting from platform expansion toward clinical proof points raises the probability that remaining cash reaches a value inflection.	Not available	+9.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
THE ATM IS Already Loaded	A $300 million at-the-market program was disclosed in February 2026 and was unused through Q1 [5]. With $556.8 million cash at June 30 against roughly $375 million annual cash opex, unassisted exhaustion sits near end-2027, so equity issuance inside the horizon is close to arithmetic certainty [1][2]. Each raise at a depressed price transfers option value from existing holders to new capital, capping per-share upside even if the science works.	Not available	-32.0%
Platform Promise Clinical Attrition REA	Seven programs are mostly Phase 1 with readouts spread across 1H27 to 2H27, and base rates for oncology assets from first-in-human to approval remain below ten percent [11]. Recursion has spent over $1.5 billion cumulatively on R&D without an approved medicine, and P/S of 37.2 leaves no cushion for a failed cohort. Sequential single-asset disappointments compound, because each one shortens the runway that funds the next.	Not available	-24.0%
FIVE Percent Discount RATE TAX	With the Fed at 3.75%-4.00%, the ten-year near 5.00% and September projections implying another hike, the most rate-sensitive cash-flow profile in equities is one with no revenue before 2030 [8]. Beta near 2.77 makes RXRX a leveraged expression of liquidity conditions rather than of its own biology [21]. Until the tightening cycle credibly turns, every clinical headline is discounted through a hostile terminal-value multiple.	Not available	-20.0%
Collaboration Revenue IS NOT A RUN RATE	Q2 2026 revenue of $7.67 million missed a $11.96 million consensus and fell from $19.22 million a year earlier; Q1 was $6.5 million against $14.7 million [1][6][7]. Recognition follows Roche project-phase completion, not commercial traction, and consensus 2026 revenue has already been cut from $52.7 million to $42.7 million [8]. Lumpy, non-repeating collaboration accounting keeps reported revenue an unreliable guide and invites repeated estimate disappointment.	Not available	-14.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
FDA Blesses THE Polyp Endpoint	If the 2H26-to-1H27 FDA interaction yields an accelerated-approval path for REC-4881 in familial adenomatous polyposis using polyp-burden reduction as a surrogate endpoint, the equity reprices from platform optionality to a defined orphan asset with pricing power and no competing therapy [10][11][23]. That would convert a diffuse terminal-value story into a datable NDA timeline, unlock partnership or royalty financing on better terms, and reduce the dilution discount. Probability stays below fifty percent because no regulatory precedent exists in FAP and natural-history data are thin.	30.0%	+85.0%
BIG Pharma BUYS THE MAPS	A strategic acquirer or an expanded Roche/Genentech-style deal with a nine-figure upfront would validate the phenomics dataset and BioHive compute as scarce infrastructure rather than a cost centre, most plausibly in 2027-2029 after clinical proof points accumulate [12][14]. With enterprise value near $1.5 billion net of cash, the platform is cheap relative to the $688 million paid for Exscientia alone [13]. A control premium or large non-dilutive upfront would remove the financing overhang outright. It stays below fifty percent because acquirers historically wait for de-risked assets, not datasets.	18.0%	+70.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Regulator Demands AN Outcomes Trial	If the FDA rejects polyp burden as a registrational surrogate and requires a multi-year colectomy-free-survival outcomes study, REC-4881's approval timeline slips beyond 2032 and its net present value collapses against a company with runway to early 2028 [2][23]. The likely trigger is the pivotal-design update now expected around late 2026 or 2027. Investors would mark the lead asset near zero and price the residual platform on cash, forcing an immediate, punitive raise. Below fifty percent because early durability data were genuinely strong.	33.0%	-48.0%
Financing ON THE Market's Terms	Should catalysts disappoint into 2027, the $300 million ATM would be drawn into weakness, followed by a discounted marketed offering and, if the price approaches one dollar, a reverse split and listing-compliance pressure [5]. That sequence is self-reinforcing: dilution depresses the price, which raises the share count needed for the next tranche. Cash operating expenses would then be cut further, slowing the very programs that justify the valuation. Below fifty percent because current cash and partner inflows give management timing flexibility through 2027.	30.0%	-42.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_115c7c63-d0dc-58f7-ba4e-4b840aa7c5fc__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	+6.0%	4.06	Catalyst-dense quarter: CGA-IGC Phase 2 data in November plus the awaited FDA registrational-path update on REC-4881 [4][11]. Anticipation and a modest opex-discipline rerating outweigh weak Q3 collaboration revenue, lifting the shares against a hawkish rate backdrop.
2	March 18, 2027	-8.0%	3.74	Post-catalyst fade. JPM guidance quantifies 2027 burn, refocusing investors on a cash balance near $400 million and an unused $300 million ATM. Fourth-quarter collaboration revenue disappoints again, compressing the platform multiple.
3	June 18, 2027	-5.0%	3.55	REC-617 combination and REC-3565 monotherapy data arrive in 1H27 as early-stage signals, not proof [11]. Interesting but insufficient against a tightening runway; financing chatter and rate pressure keep the discount rate punitive.
4	September 18, 2027	+4.0%	3.69	A partner milestone or expanded Genentech discovery scope provides non-dilutive relief and narrative support [14]. Short covering after two down quarters adds a bounce, though the equity remains hostage to 2028 funding arithmetic.
5	December 18, 2027	-14.0%	3.17	The projected dilution trough. With cash approaching the operating floor, ATM utilisation becomes visible and a marketed follow-on is priced at a discount, mechanically resetting per-share value and confirming the market's central fear.
6	March 18, 2028	+5.0%	3.33	Post-raise clearing. Funding uncertainty removed through 2029, the shares stabilise as investors re-underwrite the pipeline on a larger share count. Any easing in Treasury yields lengthens tolerable duration for pre-revenue biotech.
7	June 18, 2028	+3.0%	3.43	Registrational or expansion-cohort enrolment for REC-4881 progresses on schedule, and LSD1 monotherapy data from 2H27 are digested. Incremental operational credibility, no repricing event; drift tracks the biotech index.
8	September 18, 2028	-6.0%	3.23	Clinical attrition asserts itself: one of the early oncology programs is deprioritised on tolerability or competitive positioning. Narrower pipeline breadth reduces the aggregate option value investors assign to the platform.
9	December 18, 2028	+4.0%	3.36	Year-end catalyst calendar and renewed partner interest in the phenomics dataset lift sentiment. Cost base now structurally below the 2025 peak, so each quarter of cash preservation extends the decision window modestly.
10	March 18, 2029	-3.0%	3.25	Guidance season resets expectations again. With commercial revenue still absent and consensus pushing first material product sales past 2030, valuation reverts toward cash plus a thin pipeline premium [8].
11	June 18, 2029	+5.0%	3.42	Interim registrational data or a second pharma collaboration upfront provides validation. If the rate cycle has turned by now, the duration discount compresses, amplifying a moderate fundamental improvement into a larger price move.
12	September 18, 2029	-6.0%	3.21	Second financing window. Cash from the 2027-2028 raise nears depletion against continued $300-350 million annual burn, prompting further issuance and renewed per-share dilution pressure ahead of pivotal readouts.
13	December 18, 2029	+3.0%	3.31	Funding secured, attention returns to the registrational timeline. Pre-readout positioning builds as specialist biotech funds accumulate ahead of the most consequential dataset in the company's history.
14	March 18, 2030	-2.0%	3.24	Quiet quarter with no scheduled data. Operating losses continue, and the market applies its habitual discount to a company that has now spent over a decade without an approved medicine.
15	June 18, 2030	+6.0%	3.44	Projected pivotal readout window for the lead FAP asset. Base case assumes a mixed-to-favourable result sufficient to support a filing, driving a meaningful but incomplete repricing given remaining regulatory uncertainty.
16	September 18, 2030	-5.0%	3.27	Post-readout profit-taking and commercial-scale scepticism. FAP addresses roughly 50,000 patients, so investors debate whether orphan pricing can ever cover a cost base built for platform-scale discovery [11].
17	December 18, 2030	+3.0%	3.36	Regulatory submission progress and commercial preparation spending begin. Modest gains as execution risk shifts from clinical to launch, a transition markets typically reward with a small multiple expansion.
18	March 18, 2031	-2.0%	3.30	Pre-launch investment raises the burn again just as investors expected discipline. Working-capital build and commercial hiring offset regulatory progress, leaving the shares range-bound into the review period.
19	June 18, 2031	+4.0%	3.43	Approval decision window approaches with favourable odds given the unmet need and durability data. Partner economics on second-wave assets provide supplementary support, though share count is materially higher than 2026.
20	September 18, 2031	-2.0%	3.36	Horizon close: first commercial revenue is small relative to accumulated dilution. The platform thesis survives but per-share value ends near the 2026 anchor, confirming the dilution-tax framing of this investment.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Recursion Pharmaceuticals (RXRX) Stock Price & Overviewstockanalysis.com
[2]Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Recursion Pharmaceutic - Benzingabenzinga.com
[3]recursionjpm2026presentasec.gov
[4]Recursion Pharmaceuticals (RXRX) Earnings Report Q2 2026 | Miss, EPS & Revenue | 24/7 Wall St.247wallst.com
[5]Recursion Pharmaceuticals (RXRX) | Trefis | Trefistrefis.com
[6]Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss - Simply Wall St Newssimplywall.st
[7]Recursion Reports First Quarter Financial Results and Provides Business Update | Recursion Pharmaceuticals, Inc.ir.recursion.com
[8]Recursion Pharmaceuticals (NasdaqGS:RXRX) Stock Forecast & Analyst Predictions - Simply Wall Stsimplywall.st
[9]RXRX Forecast, Price Target & Analyst Ratings | ChartMill.comchartmill.com
[10]RECURSION PHARMACEUTICALS, INC. - Form 8-K - FY2026sec.gov
[11]MAY 6, 2026 - Recursion Pharmaceuticals, Inc.ir.recursion.com
[12]Recursion Pharmaceuticals Q2 2026 Results: OPEX guidance cut 40% to $375 millionscanx.trade
[13]Change at the top of Recursion as co-founder leaves CEO role | pharmaphorumpharmaphorum.com
[14]Recursion Pharmaceuticals, Inc. - Press Releasesir.recursion.com
[15]Recursion Q1 2026 slides: pipeline advances amid revenue shortfall By Investing.cominvesting.com
[16]Recursion Announces CEO Transition Plan to Drive Next Phase of Growthglobenewswire.com
[17]Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks - Simply Wall St Newssimplywall.st
[18]Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Pointsgenengnews.com
[19]Recursion Pharmaceuticals (RXRX) Stock Forecast & Price Targetsstockanalysis.com
[20]Recursion Pharmaceuticals (RXRX) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026public.com
[21]RXRX Stock Price | Analyst Target 6.43 & Hold Consensusetoro.com
[22]Recursion’s AI Drug Programs Show Early Clinical Progress And Valuation Gap - Simply Wall St Newssimplywall.st
[23]Recursion Eyes Breakthrough With REC-4881 Drug, But Shares Pull Back - Recursion Pharmaceuticals (NASDAQ: - Benzingabenzinga.com
[24]Recursion’s Khan Era: Proving AI Can Crack Drug Discoverywebpronews.com
[25]Recursion Pharmaceuticals (RXRX) Reports Weaker Q2 Results, Is The Valuation Gap Too Wide? - Simply Wall St Newssimplywall.st

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Ray Dalio — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.